^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    RNA polymerase inhibitor

    Related drugs:
    4d
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting | N=1266 --> 674 | Trial primary completion date: Jul 2026 --> Feb 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    rifampicin
    8d
    Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics. (PubMed, Int J Mol Sci)
    Collectively, these findings demonstrate that ONC disrupts redox homeostasis, mitochondrial function, and survival signaling in melanoma cells, exerting particularly potent effects in BRAF inhibitor-resistant populations. This study provides mechanistic insight into the anti-melanoma activity of ONC and supports its potential therapeutic application in drug-resistant melanoma.
    Preclinical • Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • CASP9 (Caspase 9) • CDK1 (Cyclin-dependent kinase 1) • ATG3 (Autophagy Related 3) • BECN1 (Beclin 1)
    |
    BRAF mutation
    |
    Tafinlar (dabrafenib) • Onconase (ranpirnase)
    10d
    Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Shaukat Khanum Memorial Cancer Hospital & Research Centre
    New trial
    |
    rifampicin
    11d
    Differential gene regulation by SR12813 and rifampicin: Insights into PXR and PPARγ activation and metabolic pathway modulation in LS180 colon cancer cells. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: SR12813 activates both pregnane X receptor and peroxisome proliferator-activated receptor gamma, demonstrating dual nuclear receptor modulation in colon cancer cells. By linking xenobiotic metabolism with lipid and mitochondrial pathways, this work uncovers previously unreported receptor crosstalk and provides a mechanistic framework for how diverse ligands can differentially shape transcriptional programs relevant to drug metabolism and tumor biology.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • NR1I2 (Nuclear Receptor Subfamily 1 Group I Member 2)
    |
    rifampicin
    11d
    Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification. (PubMed, Mater Today Bio)
    Leveraging this biomimetic platform, we conducted high-throughput drug screening and identified lurbinectedin as a potent therapeutic candidate for TETs...Integrating RNAseq data with TCGA survival analysis further identified PBX3, REPS2, and CXCR4 as potential efficacy-predictive biomarkers. This study establishes a translational framework linking 3D bioprinted TET models with biomarker discovery, offering a standardized platform for precision drug screening and mechanistic exploration in thymic epithelial tumors.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • PBX3 (PBX Homeobox 3)
    |
    Zepzelca (lurbinectedin)
    11d
    LiFFT: Lurbinectedin in FET-Fused Tumors (clinicaltrials.gov)
    P1/2, N=63, Recruiting, Children's Hospital of Philadelphia | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial primary completion date
    |
    EWSR1 (EWS RNA Binding Protein 1) • ETV1 (ETS Variant Transcription Factor 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • FUS (FUS RNA Binding Protein) • TAF15 (TATA-Box Binding Protein Associated Factor 15) • ETV4 (ETS Variant Transcription Factor 4)
    |
    Zepzelca (lurbinectedin)
    17d
    RC24_0404: Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE) (2024-518018-22-00)
    P2/3, N=422, Not yet recruiting, Centre Hospitalier Universitaire De Nantes
    New P2/3 trial • Head-to-Head
    |
    rifampicin
    17d
    BIOMARK4TB: Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment (2025-522235-34-00)
    P4, N=75, Recruiting, Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
    New P4 trial
    17d
    ISG-TULIPS: Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) (2024-519261-21-00)
    P1/2, N=20, Recruiting, Italian Sarcoma Group
    New P1/2 trial
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1)
    |
    irinotecan • Zepzelca (lurbinectedin)
    25d
    Shorter and Safer Treatment Regimens for Latent TB (clinicaltrials.gov)
    P2/3, N=1800, Recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin
    1m
    EMERGE 101: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Zepzelca (lurbinectedin)
    1m
    The efficacy and complications of rifampin-combined antibiotic therapy for staphylococcal periprosthetic joint infections: A multicenter, randomized controlled trial (ChiCTR2500114844)
    P=N/A, N=428, Not yet recruiting, The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
    New trial
    |
    rifampicin